

3 September 2025

ASX Market Announcements Office
ASX Compliance Pty Ltd
Level 40, Central Park
152-158 St Georges Terrace
Perth WA 6000

Dear Sir/Madam,

NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001 (CTH)

Botanix Pharmaceuticals Limited (ASX: BOT, **Botanix** or **the Company**) advises that today it issued 200,000 new fully paid ordinary shares (**New Shares**) on exercise of 200,000 \$0.105, 12 September 2026 unquoted options.

The Company hereby provides notification under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) of the issue of the New Shares. The Corporations Act restricts the on-sale of securities issued without disclosure unless the sale is exempt under section 708 or 708A of the Corporations Act. By the Company giving this notice (**Notice**), a sale of the New Shares will fall within the exemption in section 708A(5) of the Corporations Act and they will be able to be traded immediately.

For the purposes of section 708A(6) of the Corporations Act, the Company gives notice that:

- (a) the Company issued the New Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this Notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this Notice, the Company has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) sections 674 and 674A of the Corporations Act; and
- (d) as at the date of this Notice, there is no excluded information, within the meanings of section 708A(7) and 708A(8) of the Corporations Act.

By order of the Board



Susan Park
Company Secretary

Release authorised by the Board of Directors.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX: BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for its lead product *Sofdra*[™] for the treatment of primary axillary hyperhidrosis. *Sofdra*[™] is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more, please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Hannah Howlett

WE Communications

P: +61 450 648 064

hhowlett@we-worldwide.com

Media enquiries

Haley Chartres

H[^]CK

P: +61 423 139 163

haley@hck.digital

For personal use only